Table 3. Statistical analyses of correlation between HER2 gene copy number status and clinical data in terms of response rate (RR).
|
RR | |||
|---|---|---|---|
| All patients | Responders | Non-responders | P-value |
| N=158 | N=56 | N=102 | |
|
HER2-all-A vs others (HER2-non A and HER2-minor-A) | |||
| 6 | 2 (33%) | 4 (67%) | |
| 1.0000 | |||
| 152 |
54 (35%) |
98 (65%) |
|
|
HER2-FISH+ vs HER2-FISH− | |||
| 104 | 47 (45%) | 57 (55%) | |
| 0.0004 | |||
| 54 |
9 (17%) |
45 (83%) |
|
|
HER2-all-A vs HER2-FISH− vs HER2-FISH+* | |||
| 6 | 2 (33%) | 4 (67%) | |
| 54 | 9 (17%) | 45 (83%) | 0.0006 |
| 98 | 45 (46%) | 53 (54%) | |
Abbreviations: FISH=fluorescent in situ hybridization; HER2-all-A=HER2 gene amplification in all the sample (R:HER2/CEP17⩾2 in ⩾90% of cells); HER2-FISH+=HER2 gene copy number gain (CNG: presence of ⩾4 copies of the HER2 gene in ⩾40% of the cells) and HER2-A (HER2 gene amplification as R:HER2/CEP17⩾2 in ⩾10% of cells); HER2-FISH−=absence of CNG and absence of HER2 amplification; HER2-minor-A=HER2 gene amplification in a minor population (10–60% of cells); HER2-non-A=absence of HER2 gene amplification. Significant P-values are in bold. P-values for RR were calculated using Chi-square test.